Your cart is empty.
Clinical diagnostics company Ambry Genetics focuses on the identification of germline mutations, detecting large deletions and duplications primarily by next generation sequencing. Automation holds the key to efficient high throughput assays, ensuring optimum productivity.
Access to human pluripotent embryonic stem cells is enabling Genea Biocells to pioneer novel therapies to treat a number of neuromuscular diseases. Drawing on almost 30 years of research heritage, the company is using its expertise to model spinal muscular atrophy and facioscapulohumeral muscular dystrophy to identify potential therapies.